PMCB Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03

Price $0.40

Market Cap (MRQ) $4M

P/E (TTM) -0.2

EPS (TTM) $-2.08

Revenue (TTM) $0

ROE (TTM) -45.4%

52W Range $0–$2

PMCB Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04

range

bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

Stock splits 1

Ex-date	Split	Type
July 12, 2021	1-for-1550	Reverse

10-Year Performance Revenue, net income, margins and EPS trends

06

Revenue$0

2017-04-30 → 2026-04-30

EPS$-2.77

2021-04-30 → 2026-04-30

Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric	PMCB	5Y avg	Peer Median	Verdict
P/E (TTM)	-0.25Y avg ≈-4.6	≈-4.6	·	·
P/B (MRQ)	0.25Y avg ≈0.3	≈0.3	0.3	Undervalued
Price / Cash Flow	-0.85Y avg ≈-5.2	≈-5.2	·	·
Price / Tangible Book	0.15Y avg ≈0.4	≈0.4	·	·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric	5Y trend	PMCB	5Y avg	Peer Median	Verdict
ROA (TTM)		-39.5%5Y avg ≈0.35%	≈0.35%	-38.1%	In line
ROE (TTM)		-45.4%5Y avg ≈0.11%	≈0.11%	-256.3%	Top tier

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric	5Y trend	PMCB	5Y avg	Peer Median	Verdict
Current Ratio (MRQ)		40.35Y avg ≈59.5	≈59.5	3.6	Strong liquidity
Quick Ratio		22.85Y avg ≈54.4	≈54.4	2.3	Strong liquidity

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric	5Y trend	PMCB	5Y avg	Peer Median	Verdict
Net Income YoY		9085.0%	·	·	·

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric	PMCB	5Y avg	Peer Median	Verdict
EPS (Diluted)	$-2.775Y avg ≈$-0.37	≈$-0.37	·	·
Revenue / Share	$0.005Y avg ≈$0.00	≈$0.00	·	·
Cash Flow / Share	$-0.615Y avg ≈$-0.34	≈$-0.34	·	·
Cash / Share	$1.735Y avg ≈$13.59	≈$13.59	·	·

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric	5Y trend	PMCB	5Y avg	Peer Median	Verdict
Asset Turnover		0.05Y avg ≈0.0	≈0.0	·	·
Revenue / Employee		≈$0.00	·	·	·

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14

Period	Report	EPS Actual	EPS Est	Surprise
March 31, 2027	Sep 14, 2026	$-0.54	—	—
March 31, 2026		$-0.09	—	—
Sept. 30, 2025		$-0.10	—	—
June 30, 2025		$-0.29	—	—
March 31, 2025		$0.14	—	—

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15

Income Statement 16

Metric	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Cost of Revenue	·	·	·	·	·	·	·	·	·	·	$0	$0
Gross Profit	·	·	·	·	·	·	·	·	·	·	$0	$0
R&D Expense	$391.3K	$438.4K	$407.4K	$468.5K	$690.9K	$916.2K	$301.2K	$460.1K	$2M	$1M	$1M	$3M
SG&A Expense	$5M	$4M	$6M	$1M	$1M	$418.1K	$1M	$1M	$2M	$744.8K	$2M	$2M
Operating Expenses	$7M	$4M	$9M	$6M	$4M	$4M	$4M	$4M	$7M	$4M	$6M	$13M
Operating Income	$-7M	$-4M	$-9M	$-6M	$-4M	$-4M	$-4M	$-4M	$-7M	$-4M	$-6M	$-13M
Interest Expense	·	·	·	$0	$509	$3.0K	$453	$0	$0	$1.5K	$1.2K	$4.9K
Other Non-op	$-980	$-965	$191.1K	$202.0K	$-4.3K	$71.7K	$-493	$33.4K	$152.6K	$-1.5K	$9.3K	$3M
Income Tax	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	$-19M	$31M	$333.8K	$-4M	$-4M	$-4M	$-4M	$-4M	$-7M	$-4M	$-6M	$-10M
EPS (Basic)	$-2.77	$3.19	$-1.80	$-0.22	$-0.27	$-2.45	·	·	·	·	·	·
EPS (Diluted)	$-2.77	$3.19	$-1.80	$-0.22	$-0.27	$-2.45	·	·	·	·	·	·
Shares (Basic)	8,378,291	7,329,596	9,581,059	19,489,204	15,521,654	1,448,285	903,812	1,100,104,338	968,641,686	845,308,413	752,403,049	704,327,656
Shares (Diluted)	8,378,291	7,329,596	9,581,059	19,489,204	15,521,654	1,448,285	903,812	1,100,104,338	968,641,686	845,308,413	752,403,049	704,327,656
EBITDA	$-7M	$-4M	$-9M	$-6M	$-4M	$-4M	$-4M	$-4M	$-7M	$-4M	$-6M	·

Balance Sheet 19

Metric	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Cash & Equivalents	$19M	$15M	$50M	$68M	$85M	$2M	$894.9K	$515.3K	$1M	$3M	$2M	$3M
Short-term Investments	$254.0K	$366.3K	$0	·	·	·	·	·	·	·	·	·
Prepaid Expense	$96.9K	$223.8K	$259.8K	$107.7K	$94.2K	$73.1K	$142.8K	$138.2K	$224.1K	$74.3K	$110.0K	$1M
Current Assets	$37M	$22M	$50M	$68M	$85M	$2M	$1M	$653.4K	$1M	$4M	$2M	$4M
Intangibles	$0	$2M	$2M	$4M	$4M	·	·	·	·	·	·	·
Other Non-current Assets	$7.7K	$7.7K	·	·	·	$7.4K	$7.4K	$7.4K	$7.4K	$7.4K	$7.9K	$7.9K
Total Assets	$47M	$55M	$60M	$73M	$91M	$7M	$6M	$6M	$6M	$9M	$7M	$9M
Accounts Payable	$271.1K	$399.2K	$389.4K	$128.3K	$205.4K	$172.3K	$185.8K	$121.9K	$352.6K	$365.6K	$336.0K	$496.7K
Accrued Liabilities	$522.8K	$3M	$735.2K	$458.3K	$499.0K	$552.5K	$816.6K	$621.0K	$291.5K	$214.6K	$151.6K	$23.7K
Current Liabilities	$826.4K	$3M	$7M	$586.6K	$704.4K	$724.8K	$1M	$742.9K	$644.2K	$580.2K	$637.6K	$2M
Total Liabilities	$12M	$3M	$20M	$586.6K	$704.4K	$724.8K	$1M	$742.9K	$644.2K	$580.2K	$637.6K	$2M
Common Stock	$2.6K	$2.2K	$2.2K	$2.2K	$2.1K	$159	$109	$118.6K	$101.3K	$90.5K	$78.1K	$73.3K
Paid-in Capital	$183M	$181M	$185M	$202M	$202M	$114M	$109M	$105M	$102M	$97M	$91M	$86M
Retained Earnings	$-104M	$-85M	$-116M	$-116M	$-112M	$-107M	$-104M	$-100M	$-96M	$-89M	$-85M	$-79M
Treasury Stock	$45M	$45M	$42M	$14M	$0	·	·	·	·	·	·	·
AOCI	$-20.8K	$-23.9K	$-23.5K	$-23.0K	$-15.8K	$-20.4K	$-21.7K	$-13.8K	$-4.7K	$1.7K	$806	$1.5K
Stockholders' Equity	$33M	$52M	$28M	$73M	$90M	$7M	$5M	$5M	$6M	$8M	$7M	$8M
Liabilities + Equity	$47M	$55M	$60M	$73M	$91M	$7M	$6M	$6M	$6M	$9M	$7M	$9M
Shares Outstanding	10,735,649	6,795,779	8,037,624	16,793,980	20,721,047	1,590,084	1,092,425	1,186,004,505	1,013,260,644	905,349,047	781,233,338	732,760,536

Cash Flow 9

Metric	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Stock-based Comp	$892.5K	$0	$674.7K	$7.3K	$33.1K	$194.3K	$368.6K	$293.3K	$580.4K	$420.5K	$405.1K	$735.2K
Operating Cash Flow	$-5M	$-3M	$-2M	$-4M	$-4M	$-3M	$-2M	$-3M	$-5M	$-3M	$-4M	$-5M
Investing Cash Flow	$2M	$-7M	$-5M	$0	$0	$0	$0	$0	$0	$0	·	·
Stock Issued	·	·	·	$0	$87M	$5M	$3M	$2M	$3M	$5M	$4M	$4M
Stock Repurchased	$401.6K	$3M	$28M	$14M	$0	·	·	·	·	·	·	·
Net Stock Activity	$-401.6K	$-3M	$-28M	$-14M	$87M	$5M	$3M	$2M	$3M	$5M	$4M	·
Financing Cash Flow	$7M	$-25M	$-11M	$-14M	$87M	$5M	$3M	$2M	$3M	$5M	·	·
Net Change in Cash	$3M	$-35M	$-18M	$-17M	$83M	$1M	$379.6K	·	·	·	·	·
Taxes Paid	$0	$0	$1.6K	$0	$1.6K	$800	$800	$800	$800	$800	·	·

Profitability 2

Metric	Trend	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
ROA		-38.1%	53.3%	0.50%	-5.3%	-8.6%	-52.3%	-64.0%	-66.7%	-90.6%	-56.1%	-73.7%	·
ROE		-56.7%	66.5%	1.1%	-5.8%	-4.7%	-49.7%	-81.3%	-78.2%	-117.7%	-60.8%	-84.8%	·

Liquidity & Solvency 3

Metric	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Current Ratio	45.3	7.7	6.8	116.2	121.4	3.1	1.0	0.9	2.0	6.1	3.2	·
Quick Ratio	22.8	5.3	6.8	116.0	121.2	3.0	0.9	0.7	1.6	6.0	3.0	·
Interest Coverage	·	·	·	·	-8628.7	-1189.4	-8446.8	·	·	-2886.4	-5099.2	·

Efficiency 1

Metric	Trend	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Asset Turnover		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	·

Per Share 5

Metric	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Book Value / Share	$3.10	$7.64	$3.44	$4.33	$56.55	$4.20	$0.00	$0.00	$0.01	$0.01	$0.01	·
Revenue / Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	·
Cash Flow / Share	$-0.61	$-0.41	$-0.22	$-0.19	$-0.27	$-2.30	$-0.00	$-0.00	$-0.01	$-0.00	$-0.01	·
Cash / Share	$1.73	$2.23	$6.24	$4.05	$53.71	$1.38	$0.00	$0.00	$0.00	$0.00	$0.00	·
EPS (TTM)	$-2.77	$3.19	$-1.80	$-0.22	$-0.27	$-2.45	·	·	·	·	·	·

Growth Rates 1

Metric	Trend	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Net Income YoY		·	9085.0%	·	·	·	·	·	·	·	·	·	·

Valuation (TTM) 8

Metric	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue TTM	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Net Income TTM	$-19M	$31M	$333.8K	$-4M	$-4M	$-4M	$-4M	$-4M	$-7M	$-4M	$-6M	$-10M
Market Cap	$8M	$8M	$17M	$49M	$4M	$44M	$62.23B	$75.37B	$84.81B	$109.32B	$82.95B	·
P/E	-0.3	0.4	-1.2	-13.3	-8.6	-11.2	·	·	·	·	·	·
P/B	0.2	0.2	0.6	0.7	0.0	6.5	12227.9	14955.8	14701.8	13517.1	12716.8	·
P / Tangible Book	0.2	0.2	0.7	0.7	0.0	6.5	12227.9	·	·	·	·	·
P / Cash Flow	-1.5	-2.8	-7.9	-12.9	-0.9	-13.1	-26611.4	-26189.3	-16696.9	-32734.7	-19084.1	·
Earnings Yield	-383.7%	257.3%	-84.9%	-7.5%	-11.6%	-8.9%	·	·	·	·	·	·

Income Statement 14

Metric	Q1 2027	Q4 2026	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023
Revenue	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
R&D Expense	$60.0K	$61.9K	$93.1K	$141.1K	$95.2K	$126.7K	$118.2K	$97.5K	$96.0K	$94.2K	$126.7K	$82.0K	$104.5K	$85.9K	$45.4K	$178.0K
SG&A Expense	$946.7K	$899.9K	$2M	$1M	$753.1K	$915.9K	$842.1K	$1M	$1M	$4M	$251.9K	$272.5K	$1M	$328.1K	$356.9K	$183.0K
Operating Expenses	$1M	$3M	$2M	$1M	$848.3K	$1M	$960.3K	$1M	$1M	$3M	$2M	$1M	$2M	$903.3K	$2M	$2M
Operating Income	$-1M	$-3M	$-2M	$-1M	$-848.3K	$-1M	$-960.3K	$-1M	$-1M	$-3M	$-2M	$-1M	$-2M	$-903.3K	$-2M	$-2M
Interest Expense	·	·	·	·	·	·	·	·	·	·	·	·	·	·	$0	$0
Other Non-op	$-97	$-132	$-632	$-95	$-121	$687	$-400	$-1.1K	$-190	$194.0K	$-253	$-765	$-1.8K	$54.0K	$153.0K	$-1.1K
Income Tax	$0	·	·	·	$0	·	·	·	·	·	·	·	·	·	·	·
Net Income	$-5M	$-4M	$746.9K	$-7M	$-8M	$12M	$-3M	$-1M	$23M	$1M	$-619.5K	$3M	$-3M	$-126.3K	$-764.1K	$-2M
EPS (Basic)	$-0.54	$-0.13	$-0.17	$-1.24	$-1.23	$2.12	$-0.44	$-0.39	$1.90	$-0.35	$-0.65	$-0.26	$-0.54	$-0.02	$-0.04	$-0.09
EPS (Diluted)	$-0.54	$-0.13	$-0.17	$-1.24	$-1.23	$2.12	$-0.44	$-0.39	$1.90	$-0.35	$-0.65	$-0.26	$-0.54	$-0.02	$-0.04	$-0.09
Shares (Basic)	10,735,649	·	9,262,829	6,795,779	6,795,779	·	6,960,014	7,637,034	7,866,387	·	8,606,957	8,765,134	12,601,891	·	18,995,442	20,585,451
Shares (Diluted)	10,735,649	·	9,262,829	6,795,779	6,795,779	·	6,960,014	7,637,034	7,866,387	·	8,606,957	8,765,134	12,601,891	·	18,995,442	20,585,451
EBITDA	$-1M	·	$-2M	$-1M	$-848.3K	·	$-960.3K	$-1M	$-1M	·	$-2M	$-1M	$-2M	·	$-2M	$-2M

Balance Sheet 19

Metric	Q1 2027	Q4 2026	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023
Cash & Equivalents	$18M	$19M	$20M	$15M	$13M	$15M	$16M	$21M	$33M	$50M	$61M	$73M	$75M	$68M	$73M	$77M
Short-term Investments	$99.5K	$254.0K	$372.3K	$201.2K	$261.9K	$366.3K	$372.6K	·	·	$0	·	·	·	·	·	·
Prepaid Expense	$32.0K	$96.9K	$158.7K	$503.1K	$238.2K	$223.8K	$207.4K	$493.2K	$240.2K	$259.8K	$297.8K	$323.2K	$88.7K	$107.7K	$181.0K	$256.8K
Current Assets	$31M	$37M	$21M	$23M	$19M	$22M	$17M	$21M	$33M	$50M	$62M	$74M	$75M	$68M	$73M	$77M
Intangibles	·	$0	$2M	$2M	$2M	$2M	$2M	$2M	$2M	$2M	$4M	$4M	$4M	$4M	·	·
Other Non-current Assets	$7.7K	$7.7K	·	·	·	$7.7K	·	·	·	·	·	·	·	·	·	·
Total Assets	$37M	$47M	$56M	$56M	$45M	$55M	$44M	$55M	$70M	$60M	$71M	$79M	$80M	$73M	$78M	$82M
Accounts Payable	$390.5K	$271.1K	$1M	$1M	$465.2K	$399.2K	$484.9K	$348.6K	$554.0K	$389.4K	$484.2K	$126.2K	$718.1K	$128.3K	$445.9K	$861.3K
Accrued Liabilities	$345.7K	$522.8K	$445.7K	$520.7K	$595.7K	$3M	$709.4K	$707.2K	$684.1K	$735.2K	$774.4K	$1M	$480.0K	$458.3K	$381.9K	$449.9K
Current Liabilities	$768.7K	$826.4K	$2M	$2M	$1M	$3M	$1M	$5M	$7M	$7M	$8M	$5M	$2M	$586.6K	$827.8K	$1M
Total Liabilities	$7M	$12M	$16M	$19M	$2M	$3M	$4M	$12M	$17M	$20M	$22M	$21M	$20M	$586.6K	$827.8K	$1M
Common Stock	$2.6K	$2.6K	$2.6K	$2.2K	$2.2K	$2.2K	$2.2K	$2.2K	$2.2K	$2.2K	$2.2K	$2.2K	$2.2K	$2.2K	$2.2K	$2.2K
Paid-in Capital	$182M	$183M	$183M	$181M	$182M	$181M	$181M	$181M	$183M	$185M	$189M	$194M	$202M	$202M	$202M	$202M
Retained Earnings	$-109M	$-104M	$-100M	$-101M	$-93M	$-85M	$-97M	$-94M	$-92M	$-116M	$-117M	$-116M	$-119M	$-116M	$-116M	$-115M
Treasury Stock	$45M	$45M	$45M	$45M	$45M	$45M	$44M	$44M	·	$42M	$41M	$40M	$40M	$14M	$9M	$5M
AOCI	$-21.4K	$-20.8K	$-21.5K	$-24.1K	$-23.7K	$-23.9K	$-24.5K	$-23.3K	$-23.3K	$-23.5K	$-23.1K	$-24.1K	$-22.6K	$-23.0K	$-17.7K	$-15.2K
Stockholders' Equity	$28M	$33M	$38M	$35M	$44M	$52M	$40M	$43M	$48M	$28M	$31M	$37M	$43M	$73M	$77M	$81M
Liabilities + Equity	$37M	$47M	$56M	$56M	$45M	$55M	$44M	$55M	$70M	$60M	$71M	$79M	$80M	$73M	$78M	$82M
Shares Outstanding	10,735,649	10,735,649	10,735,649	·	6,795,779	6,795,779	6,904,894	7,034,259	7,717,278	8,037,624	8,521,159	8,699,992	8,778,101	16,793,980	18,209,018	19,526,944

Cash Flow 9

Metric	Q1 2027	Q4 2026	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023
Stock-based Comp	·	$0	$771.5K	$60.5K	$60.5K	$0	$-341.8K	$119.2K	$222.7K	$0	$674.7K	$0	$0	$0	$667	$3.9K
Operating Cash Flow	$-780.9K	$-1M	$-786.8K	$-979.5K	$-2M	$-1M	$-509.9K	$-1M	$-373.3K	$-333.0K	$-177.1K	$-2M	$343.0K	$-288.4K	$-541.7K	$-2M
Investing Cash Flow	·	$0	$5M	$-3M	$0	$0	$0	$0	$-7M	$0	$-5M	$0	$0	$0	$0	$0
Stock Issued	·	·	·	·	·	·	·	·	·	·	·	·	·	·	$0	$-880
Stock Repurchased	·	$0	$401.6K	$0	$0	$171.5K	$225.0K	$1M	$742.2K	$1M	$404.7K	$165.0K	$26M	$4M	$4M	$3M
Net Stock Activity	·	·	·	·	$0	·	·	·	$-742.2K	·	$-404.7K	$-165.0K	$-26M	·	·	·
Financing Cash Flow	$-83.4K	$-169.8K	$543.8K	$6M	$0	$-171.5K	$-4M	$-11M	$-10M	$-11M	$-7M	$748.7K	$6M	$-4M	$-4M	$-3M
Net Change in Cash	$-864.9K	$-2M	$5M	$2M	$-2M	$-1M	$-4M	$-12M	$-18M	$-11M	$-12M	$-1M	$7M	$-5M	$-4M	$-5M
Taxes Paid	·	·	·	·	·	$0	$0	$0	·	$0	$0	$0	$1.6K	$0	$0	$0

Profitability 2

Metric	Trend	Q1 2027	Q4 2026	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023
ROA		-12.4%	·	1.5%	-13.4%	-14.5%	·	-5.3%	-2.2%	31.2%	·	-0.83%	3.5%	-3.8%	·	-0.90%	-2.1%
ROE		-14.3%	·	1.9%	-18.9%	-18.3%	·	-8.5%	-3.7%	51.8%	·	-1.1%	4.7%	-4.9%	·	-0.91%	-2.2%

Liquidity & Solvency 2

Metric	Trend	Q1 2027	Q4 2026	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023
Current Ratio		40.3	·	12.3	14.6	18.0	·	14.2	4.5	4.4	·	8.2	14.1	49.2	·	88.0	58.9
Quick Ratio		23.2	·	12.2	9.9	12.7	·	14.0	4.4	4.4	·	8.1	14.0	49.2	·	87.7	58.7

Efficiency 1

Metric	Trend	Q1 2027	Q4 2026	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023
Asset Turnover		0.0	·	0.0	0.0	0.0	·	0.0	0.0	0.0	·	0.0	0.0	0.0	·	0.0	0.0

Per Share 5

Metric	Q1 2027	Q4 2026	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023
Book Value / Share	$2.56	·	$3.55	·	$6.41	·	$5.83	$6.18	$6.18	·	$3.68	$4.23	$4.87	·	$4.24	$4.15
Revenue / Share	$0.00	·	$0.00	$0.00	$0.00	·	$0.00	$0.00	$0.00	·	$0.00	$0.00	$0.00	·	$0.00	$0.00
Cash Flow / Share	$-0.07	·	·	·	$-0.29	·	·	·	$-0.05	·	·	·	$0.03	·	·	·
Cash / Share	$1.65	·	$1.88	·	$1.94	·	$2.37	$2.96	$4.23	·	$7.18	$8.44	$8.51	·	$3.99	$3.94
EPS (TTM)	$-2.08	·	$-0.52	$-0.79	$0.06	·	$0.72	$0.51	$0.64	·	$-1.47	$-0.86	$-0.69	·	$0.27	$0.27

Valuation (TTM) 8

Metric	Q1 2027	Q4 2026	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023
Revenue TTM	$0	·	$0	$0	$0	·	$0	$0	$0	·	$0	$0	$0	·	$0	$0
Net Income TTM	$-16M	·	$-3M	$-7M	$-1M	·	$20M	$23M	$27M	·	$-1M	$-1M	$-6M	·	$-6M	$-6M
Market Cap	$6M	·	$9M	·	$7M	·	$11M	$13M	$15M	·	$19M	$18M	$23M	·	$53M	$57M
P/E	-0.3	·	-1.6	-1.2	17.0	·	2.2	3.5	3.1	·	-1.5	-2.5	-3.9	·	10.7	10.9
P/B	0.2	·	0.2	·	0.2	·	0.3	0.3	0.3	·	0.6	0.5	0.5	·	0.7	0.7
P / Tangible Book	0.2	·	0.2	·	0.2	·	0.3	0.3	0.3	·	0.7	0.6	0.6	·	0.7	0.7
P / Cash Flow	-7.9	·	·	·	-3.5	·	·	·	-40.5	·	·	·	68.1	·	·	·
Earnings Yield	-361.1%	·	-64.2%	-85.0%	5.9%	·	44.9%	28.2%	32.6%	·	-67.1%	-40.6%	-25.9%	·	9.3%	9.2%

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16

Metric	2026-04-30	2025-04-30	2024-04-30	2023-04-30	2022-04-30
Revenue	$0	$0	$0	$0	$0
Net Income	$-19M	$31M	$333.8K	$-4M	$-4M
Diluted EPS	$-2.77	$3.19	$-1.80	$-0.22	$-0.27

Metric	2026-04-30	2025-04-30	2024-04-30	2023-04-30	2022-04-30
Current Ratio	45.3	7.7	6.8	116.2	121.4
Quick Ratio	22.8	5.3	6.8	116.0	121.2

Institutional owners (13F) 37 filers · $696K total · As of June 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 37

Value held $696K

New positions 3

Exited positions 5

Institutional activity — Q2 2026 vs prior quarter

New positions	Exited positions	Increased	Decreased	Net shares change
3 (-8 vs prior Q)	5 (+1 vs prior Q)	6 (0 vs prior Q)	11 (+3 vs prior Q)	-279K

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution	Value	Shares	% of tracked 13F	Type
CITADEL ADVISORS LLC	$218,203	283,381	31.36%	Shares
GEODE CAPITAL MANAGEMENT, LLC	$95,681	124,247	13.75%	Shares
CITADEL ADVISORS LLC	$66,297	86,100	9.53%	Call option
VANGUARD GROUP INC	$54,241	74,919	7.80%	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$43,719	56,778	6.28%	Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$34,536	44,853	4.96%	Shares
RENAISSANCE TECHNOLOGIES LLC	$29,250	37,987	4.20%	Shares
XTX Topco Ltd	$26,319	34,180	3.78%	Shares
NORTHERN TRUST CORP	$25,120	32,624	3.61%	Shares
JANE STREET GROUP, LLC	$23,149	30,064	3.33%	Shares
Schonfeld Strategic Advisors LLC	$20,733	26,926	2.98%	Shares
VANGUARD FIDUCIARY TRUST CO	$18,058	23,452	2.60%	Shares
EQUITEC PROPRIETARY MARKETS, LLC	$17,115	22,227	2.46%	Shares
COMMONWEALTH EQUITY SERVICES, LLC	$15,600	20,255	2.24%	Shares
Tower Research Capital LLC (TRC)	$3,764	4,888	0.54%	Shares
UBS Group AG	$3,189	4,142	0.46%	Shares
GROUP ONE TRADING LLC	$385	500	0.06%	Shares
OSAIC HOLDINGS, INC.	$232	303	0.03%	Shares
BARCLAYS PLC	$148	192	0.02%	Shares
Sachetta, LLC	$11	14	0.00%	Shares
HRT FINANCIAL LP	$11	15,451	0.00%	Shares
SBI Securities Co., Ltd.	$5	6	0.00%	Shares
BFSG, LLC	$4	5	0.00%	Shares
CoreCap Advisors, LLC	$3	4	0.00%	Shares
CALDWELL SUTTER CAPITAL, INC.	$2	2	0.00%	Shares
HARBOUR INVESTMENTS, INC.	$2	3	0.00%	Shares
MORGAN STANLEY	$2	2	0.00%	Shares
FINANCIAL CONSULATE, INC	$2	2	0.00%	Shares
NewEdge Advisors, LLC	$2	2	0.00%	Shares
MCF Advisors LLC	$1	1	0.00%	Shares
Johnson Financial Group, Inc.	$1	1	0.00%	Shares
BlackRock, Inc.	$1	1	0.00%	Shares
Abound Wealth Management	$1	1	0.00%	Shares
Accredited Wealth Management, LLC	$1	50	0.00%	Shares
CWM, LLC	$1	1	0.00%	Shares
Covestor Ltd	$0	275	0.00%	Shares
HUNTINGTON NATIONAL BANK	$0	1	0.00%	Shares

Activists & 5%+ owners 3 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer	Filed	Stake	Status	Purpose	Filing
PharmaCyte Biotech, Inc. ×2 filings	Nov. 18, 2025	74.00%	Amendment	·	SEC
Iroquois Master Fund Ltd., Iroquois Capital Management, LLC, Iroquois Capital Investment Group LLC, Richard Abbe, Kimberly Page ×6 filings	June 16, 2023	·	Initial filing	·	SEC
Nima Montazeri (1) 2 (a) (b), Silver Rock Associates, Inc. (1) 2 (a) (b), Brown Stone Capital, LP (1) 2 (a) (b) ×2 filings	July 29, 2020	·	Initial filing	Passive investment	SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 8 insiders · 2 officers · 8 directors

19

Insider	Role	Last activity	Shares owned	Buys 12m	Net 12m
Joshua Silverman	CEO and President	Jan. 7, 2026 P	416,250	3	$80,300
Carlos Trujillo	Chief Financial Officer	Nov. 20, 2023 A	·	0	$0
Michael M Abecassis	Director	March 31, 2026 J	22,292	0	$0
Jonathan Schechter	Director	March 31, 2026 J	192,500	3	$48,200
Wayne Remell Walker	Director	March 31, 2026 J	20,625	0	$0
Robert Weinstein	Director	March 31, 2026 J	41,250	0	$0
Farb Daniel Stuart	Director	Dec. 28, 2022 A	·	0	$0
Daniel Allen	Director	Dec. 28, 2022 A	·	0	$0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 1 ETF

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund	Weight	Units	As of	Source
VXF · VANGUARD INDEX FUNDS	0.00%	56,778 SH	Aug. 19, 2026	Daily

PMCB Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21

rating · 6 analysts SELL

0 0.0% Strong Buy

0 0.0% Buy

3 50.0% Hold

1 16.7% Sell

2 33.3% Strong Sell

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker	Market Cap	P/E	Rev YoY	Net Margin	ROE	Gross Margin
PMCB	$8M	-0.3	·	·	-56.7%	·
ERNA	·	·	·	·	·	·
AQB	$4M	-0.2	-21.2%	·	-315.5%	·
DRMA	·	·	·	·	·	·
GRI	$122.9K	-0.0	·	·	-256.3%	·
HCWB	·	-0.1	-97.9%	-14677.1%	-586.8%	20.0%
MBIO	·	-2.5	·	·	-30.9%	·

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

PMCB PharmaCyte Biotech, Inc. - Common Stock